Preclinical News and Research

RSS

Antibiotic that appears to control phobias may also be useful in treating addiction

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory provide further evidence that a drug known as D-cycloserine could play a role in helping to extinguish the craving behaviors associated with drug addiction.

6 Nov 2007

Non-invasive radio waves heat up nanotubes to destroy cancer

Cancer cells treated with carbon nanotubes can be destroyed by non-invasive radio waves that heat up the nanotubes while sparing untreated tissue, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center and Rice University has shown in preclinical experiments.

2 Nov 2007

Study may aid pancreatic cancer patients' response to chemo drugs

Pancreatic cancer patients face the worst survival rates compared to all other forms of human cancer as the disease is nearly impossible to diagnose at an early stage when successful treatments might be possible.

1 Nov 2007

Watching TV found to be linked to obesity and now hypertension in kids

Researchers from the University of California, San Diego; the Rady Children's Hospital - San Diego; the University of California, San Francisco; and the University of South Alabama determined that television viewing is not only linked to childhood obesity, but also to hypertension in children, according to a study published in the December 2007 issue of the American Journal of Preventive Medicine.

31 Oct 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

Blood markers can help choose best dose for antiangiogenic drugs

Scientists at Sunnybrook have new information that may help to improve the use of anti-cancer drugs designed to block the growth of new blood vessels in tumors, a process called angiogenesis that is critical to tumor growth.

25 Oct 2007

New target for Hepatocellular carcinoma therapy

Hepatocellular carcinoma (HCC) is a major health problem worldwide. Currently, the only chance for obtaining a cure in patients with HCC is by either a surgical resection or liver transplantation.

25 Oct 2007

Severely restricting calories leads to a longer life

New research now has shown for the first time that such a diet also can maintain physical fitness into advanced age, slowing the seemingly inevitable progression to physical disability and loss of independence.

24 Oct 2007

Positive results for novel anti-cancer drug ECO-4601

Researchers report positive results from a Phase I/II clinical trial of a novel anti-cancer drug which offers two modes of action.

24 Oct 2007

Amazon jungle plant compound blocks tissue destruction

Scientists at Case Western Reserve University's School of Medicine have published in the Journal of Inflammation a remarkable discovery with a natural product derived from the Amazon rainforest.

24 Oct 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Potent inhibitor of Kinesin CENP-E demonstrates tumor cell inhibition

A first-in-class, targeted investigational therapy specifically designed to inhibit a single protein that functions only during cell division shows potent activity in a broad range of cancer cell lines, say researchers from GlaxoSmithKline.

24 Oct 2007

Combo therapy flavopiridol and cisplatin shows promise for recurrent ovarian cancer resistant to platinum therapy

Mayo Clinic has reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy.

24 Oct 2007

Orexigen presents findings on obesity drug candidates

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, has presented the results of a preclinical study that further supports the Company's understanding of an aspect of the mechanism of action of Contrave, one of its two late-stage obesity drug candidates.

24 Oct 2007

Experimental cancer pharmaceuticals under trial

A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro: Abstract A 111.

24 Oct 2007

Severely restricting calories leads to a longer life

22 Oct 2007

More educated people who develop dementia lose their memory faster

People with more years of education lose their memory faster than those with less education in the years prior to a diagnosis of dementia, according to a study by researchers at Albert Einstein College of Medicine of Yeshiva University, published in the October 23rd issue of the medical journal Neurology.

22 Oct 2007

GenVec receives extra funding for adenovector-based HIV vaccines program

GenVec, Inc. has announced that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has executed its sixth option period (year seven) under its multi-year collaboration with GenVec to develop and manufacture novel adenovector-based HIV vaccines.

22 Oct 2007

Abbott creates one molecule with two antibody functions

Abbott has reported that its scientists are the first to discover a proprietary technology that combines the function and specificity of two or more monoclonal antibodies (mAbs) into one molecular entity that demonstrates drug-like properties and manufacturing feasibility.

19 Oct 2007

Existing drugs may be useful in treating brain tumors

Scientists have shown how developing brain tumors can turn an encounter with a signaling molecule from a fatal experience for the tumor cells into a cue for their own growth and multiplication.

17 Oct 2007